PureTech Health (LON:PRTC) Shares Up 14.6% – Still a Buy?

PureTech Health plc (LON:PRTC) was up 14.6% on Saturday . The company traded as high as GBX 118 ($1.54) and last traded at GBX 118 ($1.54). Approximately 1,623,564 shares changed hands during mid-day trading, an increase of 54% from the average daily volume of 1,056,594 shares. The stock had previously closed at GBX 103 ($1.35).

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group reissued a “buy” rating and issued a GBX 455 ($5.96) target price on shares of PureTech Health in a research note on Monday, December 16th.

PureTech Health Stock Performance

The stock’s 50 day moving average price is GBX 135.24 and its 200 day moving average price is GBX 148.08. The company has a current ratio of 3.68, a quick ratio of 2.51 and a debt-to-equity ratio of 45.82. The company has a market capitalization of £354.45 million, a price-to-earnings ratio of -4.84 and a beta of 1.02.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.